KPIs & Operating Metrics(New)
Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsNon-Current AssetsNon-Current Deferred Tax LiabilityOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Neogenomics (NEO) Current Assets (2016 - 2025)

Neogenomics' Current Assets history spans 16 years, with the latest figure at $376.3 million for Q4 2025.

  • For Q4 2025, Current Assets fell 36.87% year-over-year to $376.3 million; the TTM value through Dec 2025 reached $376.3 million, down 36.87%, while the annual FY2025 figure was $376.3 million, 36.87% down from the prior year.
  • Current Assets reached $376.3 million in Q4 2025 per NEO's latest filing, down from $382.5 million in the prior quarter.
  • In the past five years, Current Assets ranged from a high of $942.7 million in Q1 2021 to a low of $376.3 million in Q4 2025.
  • Average Current Assets over 5 years is $598.1 million, with a median of $593.1 million recorded in 2024.
  • Peak YoY movement for Current Assets: soared 337.58% in 2021, then plummeted 36.87% in 2025.
  • A 5-year view of Current Assets shows it stood at $681.5 million in 2021, then dropped by 11.18% to $605.3 million in 2022, then dropped by 1.4% to $596.8 million in 2023, then dropped by 0.13% to $596.0 million in 2024, then tumbled by 36.87% to $376.3 million in 2025.
  • Per Business Quant, the three most recent readings for NEO's Current Assets are $376.3 million (Q4 2025), $382.5 million (Q3 2025), and $392.6 million (Q2 2025).